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ABSTRACT.  The combination of aspirin, a thienopyridine derivative, and a glycoprotein IIb/IIIa receptor
inhibitor has become standard therapy for patients undergoing percutaneous coronary intervention (PCI).
Recent studies have shown an increased incidence of thrombocytopenia in those patients receiving a
high loading dose of clopidogrel (thienopyridine) with abciximab (IIb/IIIa receptor inhibitor) prior to
coronary intervention. We reviewed the records of 504 patients who underwent PCI at a large tertiary
care hospital and noted an incidence of thrombocytopenia of 4.8%, comparable to published historical
controls who received abciximab without clopidogrel. In patients undergoing PCI, there was no difference
in thrombocytopenia or bleeding complications between patients receiving a high or a low dose of a
thienopyridine. We conclude that a high loading dose of a thienopyridine derivative prior to PCI may
be administered safely and efficaciously in the setting of concomitant administration of abciximab
without an undue risk of thrombocytopenia.
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INTRODUCTION
Platelet mediated acute and subacute thromboses are
serious complications of intracoronary stent placement.
Data from the late 1990s demonstrated the efficacy and
safety of combined therapy with aspirin and a
thienopyridine derivative for reducing stent subacute
thrombosis rates from 2% to as low as 0.5% (Moussa
and others 1999; Bage and others 1998; Leon and others
1998; CAPRIE 1996). Additionally, recent data has
demonstrated a reduction in subacute thrombosis in
patients receiving a loading dose of a thienopyridine
derivative prior to percutaneous coronary intervention
(PCI) (Steinhubl and others 1998). Higher loading doses
of clopidogrel or ticlopidine result in more rapid plate-
let inhibition, which translates into a lower total major
adverse cardiac event rate (Pache and others 2002; Bhatt
and others 2001; Gawaz and others 2001). More recent
data has shown the utility of also administering glyco-
protein (Gp) IIb/IIIa antagonists in patients undergoing
PCI to further reduce major adverse cardiac events
(EPIC 1994).
Glycoprotein IIb/IIIa inhibitors themselves may in-
duce thrombocytopenia (Berkowitz and others 1997,
1998). Recent observational data has suggested that
triple antiplatelet therapy with aspirin, a thienopyridine
derivative, and a Gp IIb/IIIa antagonist for PCI may be
associated with an unacceptably high incidence of
thrombocytopenia measured at 24% with a 300 mg
loading dose of clopidogrel (Dillon and others 2000).
This antiplatelet combination is currently administered
in up to 60% of patients undergoing PCI in the United
States, and therefore has important implications (Dillon
and others 2000). However, in our clinical experience,
we have not observed excessive thrombocytopenia
with this combination of medications. We therefore
sought to evaluate this important clinical issue by analyz-
ing our prospectively collected data over a one-year
period at a tertiary care community hospital.
MATERIALS AND METHODS
We reviewed the medical records and catheter-
ization reports from 520 patients who underwent PCI
between 1 January 1999 and 31 December 1999 at Akron
City Hospital (part of the Summa Health System), a 530-
bed tertiary care community hospital in Akron, OH.
Patients were excluded from the study if emergent
reversal of antiplatelet therapy was required; data was
incomplete; or aspirin, a thienopyridine derivative, or
a Gp IIb/IIIa receptor blocker was not administered.
Patients who underwent PCI received either ab-
ciximab (a chimeric Fab Gp IIb/IIIa receptor blocker)
bolus and infusion at the time of and beyond PCI, or
tirofiban (a synthetic peptide Gp IIb/IIIa receptor
blocker) infusion prior to and beyond PCI per FDA
guidelines (PDR 2002).
The particular thienopyridine derivative (clopidogrel
or ticlopidine) and dosage was at the interventionalist’s
discretion. Patients receiving 75 mg to 150 mg of clopid-
ogrel on the day prior to the procedure or the morning of
the procedure were classified as the Low Loading Dose
Clopidogrel group (LLDC). Patients who received 300
mg to 375 mg were classified as the High Loading Dose
Clopidogrel group (HLDC). Patients who received 250
mg to 500 mg of ticlopidine were classified as the Low
Loading Dose Ticlopidine group (LLDT). Patients who
received 1000 mg were classified as the High Loading
Dose Ticlopidine group (HLDT).
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Platelet counts obtained prior to PCI were compared
with platelet counts at 2 to 4 hours, 18 to 24 hours, and
48 to 72 hours following PCI. Thrombocytopenia was
defined as a platelet count less than 100,000 platelets/
mm3. Severe thrombocytopenia was defined as a plate-
let count less than 20,000 platelets/mm3. Hemoglobin
levels were obtained before PCI and at the documented
nadir up to 72 hours following PCI.
Other patient data assessed included age, sex, weight,
serum creatinine, diagnosis of hypertension, diabetes
mellitus, hyperlipidemia, tobacco abuse, bleeding com-
plications, requirement for transfusion of blood
products, and the length of stay after PCI. Medical
information such as treated or untreated hypertension,
diabetes mellitus, hyperlipidemia, and renal function
were obtained by chart review of initial history and
physical, initial nursing assessment and vital signs, and
laboratory data. Bleeding complications and transfusion
requirements were obtained through chart review of the
entire length of stay. Length of hospital stay was defined
as date of intervention until the day of hospital discharge.
Statistical Analysis
The analysis performed used both descriptive and
inferential statistics. The inferential statistics used both
Chi Squares and F tests. The Pearson correlation and
analysis of covariance were also employed. A power
analysis was run to determine the likelihood of making
a Type II error. Confidence intervals were also calcu-
lated. The F test is also very robust; that is, the assumptions
that the variance of the criterion measures is the same
for each of the treatment populations and that the
criterion measures for each treatment population are
normally distributed “can be violated in most cases with-
out seriously distorting the stated alpha level” (McNeil
and others 1996). The F calculation was performed
using the formula presented by McNeil and others (1996):
   F =
Where:
R2f = the proportion of observed variance (of the
dependent variable) accounted for by the full
linear regression model.
R2r = the proportion of observed variance (of the
dependent variable) accounted for by the
restricted linear regression model.
df
n
 = the number of linearly independent vectors
in the full linear regression model minus the
number of linearly independent vectors in
the restricted linear regression model.
df
d
 = the number of participants minus the number
of linearly independent vectors in the full
linear regression model.
A power analysis (McNeil and others 1996) calcu-
lation was performed using the following formulas:
L = f 2 * df
2
Where:
L = a function of power (needed to enter power tables)
(R2f - R2r)/df
n
(1 - R2f)/df
d
f2 = effect size
df
2
 = N – m
1
N = number of participants
m
1
 = number of independent vectors in the
restricted regression equation
m
2
 = number of independent vectors in the
restricted model
df
1
 = m
1
 - m
2
The next test was performed on the general linear
model test to determine if the variables of interest were
significant while holding constant the covariants.
RESULTS
Study Groups
Of the 520 patient charts reviewed, 16 were exclud-
ed for the following reasons: 6 patients died unrelated
to thrombocytopenia within 24 hours of PCI resulting
in incomplete data; 4 coronary artery perforations re-
quired immediate cessation and reversal of platelet
inhibition; 3 patients did not receive a Gp IIb/IIIa
receptor blocker; 1 patient did not receive a thienopy-
ridine derivative; 1 patient had an ascending aortic
aneurysm requiring surgical intervention, and 1 patient
had a pulmonary artery rupture secondary to pulmonary
artery catheter insertion requiring immediate cessation
and reversal of platelet inhibition. After the above
exclusions, 504 patients were included in data interpre-
tation (Table 1). Of the 504 patients, 490 received the
Gp IIb/IIIa inhibitor abciximab and 14 received tiro-
fiban. Two hundred fifty-four patients received a low
loading dose of clopidogrel (LLDC) and 145 received a
high loading dose of clopidogrel (HLDC). One hundred
two patients received a low loading dose of ticlopidine
(LLDT) and 3 patients received a high loading dose of
ticlopidine (HLDT).
TABLE 1
Number of patients receiving each combination of medication.
Abciximab Tirofiban Total
LLDC * 245 9 254
HLDC ** 141 4 145
LLDT ‡ 101 1 102
HLDT ‡‡ 3 0 3
   Total 490 14 504
* LLDC = Low Loading Dose Clopidogrel (75-150 mg).
** HLDC = High Loading Dose Clopidogrel (300-375 mg).
‡ LLDT = Low Loading Dose Ticlopidine (250-500 mg).
‡‡ HLDT = High Loading Dose Ticlopidine (1000 mg).
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Demographics
Demographic characteristics are shown in Table 2.
There were 318 males and 186 females with ages ranging
from 27-93 years, with an average age of 63 years old.
Of the 504 patients, 167 had diabetes mellitus; 319 had
hypertension; 153 had current tobacco abuse, and 135
patients had a history of remote tobacco abuse; 284 had
hyperlipidemia. Serum creatinine ranged from 0.1-9.8
mg/dl, with an average of 1.1 mg/dl. Forty-seven
patients had a serum creatinine >1.5 mg/dl.
TABLE 2
Patient demographics and risk factors.
Variables
Patients 504
Males 318
Age Mean 63 y (27-93)
Diabetes 167
Hypertension 319
Current Smoker 153
Remote Smoker 135
Hyperlipidemia 284
Creatinine Mean 1.1 mg/dL (0.1-9.8)
Creatinine  >1.5 47
Incidence of Thrombocytopenia
Of the 504 patients who underwent PCI and re-
ceived both a thienopyridine derivative and a GP IIb/
IIIa receptor blocker, 24 (4.8%) developed throm-
bocytopenia. Only one patient had severe profound
thrombocytopenia with a platelet count nadir of 3000
platelets/mm3. No other patients had platelet counts
below 52,000 platelets/mm3. Table 3 demonstrates the
incidence of thrombocytopenia for each group. Two of
the patients developed pseudothrombocytopenia re-
lated to EDTA clumping and did not have thrombo-
cytopenia on repeat analysis of heparinized samples.
Nine (3.7%) of the 245 patients who received LLDC
and abciximab had documented thrombocytopenia.
Two of the patients had low platelets (116,000 platelets/
mm3 and 128,000 platelets/mm3, respectively) prior to
administration of LLDC, resulting in nadir platelet
counts of 77,000 platelets/mm3 and 82,000 platelets/
mm3, respectively. One (11%) of the 9 patients who
received LLDC and tirofiban had thrombocytopenia.
Bleeding complications among the LLDC group in-
cluded 10 vascular access site hematomas, 3 gastro-
intestinal bleeds, 3 patients with hematuria, 2 retro-
pertinoneal hemorrhages, 1 pulmonary hemorrhage, 1 vit-
reous hemorrhage, and 1 subconjunctival hemorrhage.
TABLE 3
Incidence of thrombocytopenia for each combination of medication.
Abciximab Tirofiban Total
LLDC 9/245 (3.7%) * # ‡ 1/9 (11% ) * 10/254 (3.9%)
HLDC 6/141 (4.2%) # 0/4 6/145 (4.1%)
LLDT 8/101 (7.9%) † ‡ 0/1 8/102 (7.8%)
HLDT 0/3 † 0/0 0/3
   Total 23/490 (4.7%) 1/14(7.1%) 24/504 (4.8%)
Incidence of thrombocytopenia (platelet count <100,000 platelets/mm 3)
among patients receiving different dosages of a thienopyridine and a Gp
IIb/IIIa derivative.
* (abciximab-LLDC vs tirofiban-LLDC) c 2 = 6.4 {significant, N very small.
One needs to question the stability of this result.}
# (abciximab-LLDC vs abciximab-HLDC) c 2 = 0.6 {NS}.
† (abciximab-LLDT vs abciximab-HLDT) c 2 = 4 {significant, N very small.
One needs to question the stability of this result.}
‡ (abciximab-LLDC vs abciximab-LLDT) c 2 = 0.029 {NS}.
Only 1 of the patients with gastrointestinal blood loss
had documented thrombocytopenia.
Six of 141 (4.2%) patients who received HLDC and
abciximab had documented thrombocytopenia during
the 2-72 hour window after PCI. None of the 4 patients
who received HLDC and tirofiban had documented
thrombocytopenia. Eight patients in the HLDC group
suffered from a vascular access site hematoma; three of
these had thrombocytopenia. Four patients in the HLDC
group had gastrointestinal blood loss; only one of these
had thrombocytopenia. Three other patients in the
HLDC group had a bleeding complication from hema-
turia, intracranial hemorrhage, or epistaxis; none had
documented thrombocytopenia.
Eight (7.9%) of the 101 patients who received LLDT
and abciximab had thrombocytopenia. One patient re-
ceived LLDT and tirofiban without documented throm-
bocytopenia. There were 8 bleeding complications in
patients who received LLDT, including 5 groin hema-
tomas, 2 patients with gastrointestinal blood loss, and 1
patient with hemoptysis. None of these patients had
documented thrombocytopenia.
None of the 3 patients who received HLDT and ab-
ciximab had thrombocytopenia. Two of the 3 patients
in the HLDT group had a bleeding complication: one
patient had a vascular access site hematoma and the
other had a retroperitoneal hemorrhage. No patients
received HLDT and tirofiban.
Comparison of Study Groups
There was a significant increase in the percentage of
patients who developed thrombocytopenia and re-
ceived LLDC/tirofiban compared with LLDC/abciximab
(Table 3). However, the N was very small and the
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statistical stability of this result was questionable. There
was no percentage difference in thrombocytopenia
between patients receiving LLDC/abciximab and HLDC/
abciximab, with 93.5% confidence. More patients in the
LLDT/abciximab group developed thrombocytopenia
than in the HLDT/abciximab group; however, again N
was small and the statistical stability of this comparison
was questionable. Lastly, there was no significant differ-
ence in thrombocytopenia incidence between patients
receiving LLDC/abciximab and LLDT/abciximab.
Bleeding Complications
Fifty-one patients received blood transfusions during
their hospital stay. Vascular access site hematoma and
catheterization site oozing were the most common reasons
for blood transfusion. This was followed by “no identi-
fiable source of blood loss,” GI blood loss, preexisting
anemia with renal failure, preexisting anemia without
renal failure, retroperitoneal hemorrhage, pulmonary
hemorrhage, hematuria, and intracranial hemorrhage.
Eight patients received platelet transfusions: 5 patients
were given platelets for vascular access site hematoma
or catheterization site ooze requiring blood transfusion,
1 patient for retroperitoneal hemorrhage, 1 patient for
pulmonary hemorrhage, and 1 patient who developed
severe profound thrombocytopenia was transfused
with platelets for a nadir platelet count of 3,000 but had
no bleeding complications.
The length of stay ranged from 1-29 days with an
average of 3 days. One hundred eight-two patients had
a 1 day stay; 124 patients were discharged on day 2; 70
patients were discharged on day 3; and 128 patients had
a length of stay >3 days.
With a sample of 504 subjects, and an incidence rate
of 4.8% of thrombocytopenia, the researchers are 95%
confident that the upper limit of incidence of throm-
bocytopenia would not exceed 8.8% with any combin-
ation of thienopyridine derivative and Gp IIb/IIIa
antagonist. We are also 99% confident that the upper
limit of thrombocytopenia will not exceed 9.8%. (If the
assumption of distribution normality was extremely
violated, we would still be 75% confident that the rate
of incidence would not exceed 9.8%.) These are con-
sidered very conservative confidence estimates.
DISCUSSION
Using the general linear model (McNeil and others
1996), we found the overall incidence of thrombocy-
topenia in patients who received a combination of a
high loading dose thienopyridine derivative with in-
fusion of a Gp IIb/IIIa receptor blocker to be 4.8%.
This is similar to the 2.5-5.2% incidence of thrombo-
cytopenia observed with aspirin and a Gp IIb/IIIa
receptor blocker without a thienopyridine in prior
studies (EPIC 1994). In patients receiving aspirin and a
Gp IIb/IIIa inhibitor, there was no statistically signifi-
cant difference in thrombocytopenia between patients
receiving the high or low loading dose of either thieno-
pyridine derivative. Furthermore, there was no statistically
significant difference in the incidence of thrombo-
cytopenia between patients receiving either clopidogrel
or ticlopidine (whether high or low loading dose). Despite
the low numbers of patients receiving tirofiban, we
detected no difference in thrombocytopenia between
patients receiving either abciximab or tirofiban regard-
less of the thienopyridine or dose administered. Lastly,
there was no significant correlation between the high
loading dose thienopyridine group and an increased
incidence of bleeding complications or transfusion of
blood products.
Subacute thrombosis following stent placement has
been dramatically reduced since the introduction of
aggressive platelet inhibition directed at multiple sites of
platelet activation. First the introduction of the thieno-
pyridine derivatives against the platelet ADP receptor
in conjunction with aspirin dramatically reduced the
incidence of subacute thrombosis. The more favorable
side effect profile offered by clopidogrel over ticlo-
pidine has made ADP receptor blockade safer and
better tolerated (Pache and others 2002; Taniuchi and
others 2001; Mishkel and others 1999; Moussa and others
1999). With the addition of chimeric antibody fragments
and small molecules directed against the platelet gly-
coprotein IIb/IIIa receptor, major adverse cardiac events
have been further reduced.
Concerns have mounted that platelet inhibition,
particularly with the use of a high loading dose of
clopidogrel in combination with a Gp IIb/IIIa recep-
tor inhibitor may cause excessively high rates of
druginduced thrombocytopenia (Dillon and others
2000). Additionally, the concomitant use of three anti-
platelet agents has raised the concern about potential
bleeding complications, particularly in those receiving
a high loading dose of a thienopyridine derivative
(Pache and others 2002; Bertrand and others 2000).
Our results, however, support the safety of the use of
a high loading dose of a thienopyridine derivative prior
to PCI.
The strength of this study relies upon the use of
power analysis (McNeil and others 1996) (0.90 for
detecting small effect sizes, f 2 = 0.02, a = 0.05, N = 504)
and very conservative confidence estimates. Potential
limitations include the fact that the patients were treated
in a non-randomized fashion at the interventionalist’s
discretion, which may incorporate an unknown or un-
detected clinical bias in treatment decisions. Further-
more, there were only 14 patients treated with the small
molecule tirofiban as opposed to the antibody fragment
abciximab. Fewer patients received ticlopidine than
clopidogrel and there were only three patients who
received a high loading dose of ticlopidine.
Therefore, the use of a high initial loading dose of
clopidogrel or ticlopidine to maximize platelet in-
hibition combined with aspirin and a Gp IIb/IIIa
receptor blocker prior to PCI is both beneficial and
safe. We advocate appropriate clinical monitoring for
thrombocytopenia, blood loss, and other rare but
potentially serious side effects of thienopyridine
derivatives. We conclude that a high loading dose of
clopidogrel or ticlopidine should be part of routine
therapeutics. Due to the better side effect profile, clo-
pidogrel may be the preferred agent.
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